Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

2.52
-0.0700-2.70%
Post-market: 2.51-0.0100-0.40%16:12 EDT
Volume:23.17K
Turnover:59.02K
Market Cap:23.82M
PE:-1.14
High:2.59
Open:2.56
Low:2.50
Close:2.59
52wk High:6.52
52wk Low:2.20
Shares:9.45M
Float Shares:9.01M
Volume Ratio:0.58
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2100
EPS(LYR):-8.3544
ROE:-119.57%
ROA:-58.44%
PB:0.80
PE(LYR):-0.30

Loading ...

Company Profile

Company Name:
Cellectar Biosciences
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
11
Office Location:
100 Campus Drive,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Directors

Name
Position
Douglas J. Swirsky
Chairman of the Board and Independent Director
James V. Caruso
Director,Chief Executive Officer and President
Andrew Gu
Independent Director
Asher Chanan Khan
Independent Director
Frederick W. Driscoll
Independent Director
John Neis
Independent Director

Shareholders

Name
Position
James V. Caruso
Director,Chief Executive Officer and President
Jarrod Longcor
Chief Operating Officer
Chad J. Kolean
Vice President, Secretary and Chief Financial Officer
Douglas J. Swirsky
Chairman of the Board and Independent Director